CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing a new generation of synthetic enzymes, specifically single chain polymer nanoparticles, to activate prodrugs directly at tumor sites. By enhancing the structure and function of these nanoparticles, the aim is to improve targeted drug therapy while minimizing side effects associated wi…
Cancer continues to be a major cause of death worldwide.
While many drugs can reduce the size of tumors, their side effects commonly outweigh their benefits when the drug is administered by conventional methods.
One promising approach to overcome this issue is to employ a synthetic enzyme to activate a prodrug into an active drug via a bioorthogonal reaction at the site of a tumor within a patient.
Recent work by the group of Prof. E. W.
Meijer at the Eindhoven University of Technology on amphip…
TECHNISCHE UNIVERSITEIT EINDHOVEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
